[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CHU de Quebec-Universite Laval\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":684},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,59,93,119,146,176,219,240,263,286,310,337,369,393,415,442,463,492,517,545,565,599,628,661],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100630129","non-inferiority-study-comparing-salvage-pelvic-radiotherapy-in-25-fractions-625-gy25-versus-20-fractions-525-gy20-for-recurrent-prostate-cancer-after-surgery-100630129",false,"NCT07483658","Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy\u002F25) Versus 20 Fractions (52.5 Gy\u002F20) for Recurrent Prostate Cancer After Surgery.","Non-Inferiority Study Comparing Hypofractionated Post-Operative Salvage Radiotherapy Regimens: 45\u002F62.5 Gy in 25 Fractions vs. 43\u002F52.5 Gy in 20 Fractions for Grade 2+ GU or GI Toxicity (HYP-OP-RT)","HYP-OP-RT","Inclusion Criteria:\n\n* Histologically confirmed prostate adenocarcinoma.\n* Prior radical prostatectomy with detectable PSA (≥0.2 ng\u002FmL).\n* No evidence of distant metastasis (confirmed via bone scan and CT\u002FMRI or TEP-PSMA if PSA is above 0.5 ng \u002Fml).\n* Patient with Nodal recurrence within the pelvis are eligible\n* ECOG performance status 0-2.\n* Age ≥ 18 years.\n* Adequate baseline renal, hepatic, and hematologic function.\n\nExclusion Criteria:\n\n* Prior pelvic radiotherapy.\n* Macroscopic local relapse on imaging\n* Presence of metastatic disease.\n* Active inflammatory bowel disease or other GI conditions predisposing to radiation toxicity.\n* Uncontrolled comorbidities affecting study participation.\n* Prior systemic therapy for recurrent prostate cancer (except ADT within 6 months).","MALE","18 Years",{"count":20,"type":21},434,"ESTIMATED","INTERVENTIONAL",[24],"NA","Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA). The goal is to see if a shorter treatment schedule is as safe and effective as the standard schedule.\n\nWhy is this study important? After prostate surgery, cancer can return in up to 70-80% of high-risk patients. Radiotherapy helps control this, but the best way to deliver it-especially the number of sessions and whether to treat the pelvic area-is still being studied. Shorter treatments could mean less time in therapy and better quality of life, if such treatments are proven safe.\n\nWhat is being compared?\n\nStandard treatment (Arm A):\n\n25 sessions (about 5 weeks) Prostate bed: 62.5 Gy Pelvis: 45 Gy\n\nShorter treatment (Arm B):\n\n20 sessions (about 4 weeks) Prostate bed: 52.5 Gy Pelvis: 43 Gy\n\nBoth groups may also receive hormone therapy (ADT) for 6-24 months.\n\nMain Goal To check if the shorter treatment causes no more side effects (urinary or bowel problems) than the standard treatment, while keeping cancer control similar.\n\nOther Things to be Measured\n\nCancer control (PSA levels, spread of disease) Survival Quality of life (urinary, bowel, sexual health questionnaires)\n\nWho can join?\n\nMen who:\n\nHad prostate surgery Have a detectable PSA (≥0.2 ng\u002FmL) No distant metastasis Are in good general health (ECOG 0-2)\n\nHow long will the study last?\n\nAbout 12 years total:\n\n2 years to enroll patients 10 years of follow-up",[27,28,29,30,31,32],"Reccurent\u002FMetastatic Solid Tumor Disease","Prostate Cancer (Post Prostatectomy)","Prostate Cancer","Prostatic Neoplasms","Neoplasm Recurrence, Local","Biochemical Recurrence of Malignant Neoplasm of Prostate",[34,35,36,37,38,39,40,41,42,43,44,45],"Radiotherapy, Adjuvant","Radiotherapy, Intensity-Modulated","Radiotherapy, High-Dose Hypofractionated","Pelvic Radiotherapy","Androgen Deprivation Therapy","Randomized Controlled Trials","Noninferiority Trials","Quality of Life","Treatment Outcome","Gastrointestinal Diseases \u002F chemically induced","Urinary Tract Diseases \u002F chemically induced","Radiation Injuries","RECRUITING","2026-06-29",{"date":49,"type":50},"2026-07-01","ACTUAL",{"date":52,"type":50},"2026-05-13",{"date":54,"type":21},"2036-02",{"name":56,"class":57},"CHU de Quebec-Universite Laval","OTHER",4,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100644039","obediam-therapeutic-patient-education-in-adults-living-with-obesity-diabetes-and-metabolic-disorders-100644039","NCT07668661","OBEDIAM: Therapeutic Patient Education in Adults Living With Obesity, Diabetes, and Metabolic Disorders","OBEDIAM: a Pilot Study of Therapeutic Patient Education in Adults Living With Obesity, Diabetes, and Metabolic Disorders","OBEDIAM","Inclusion Criteria:\n\n* Aged 18 to 80\n* living with obesity defined by a BMI ≥ 30 kg\u002Fm2 with a stage ≥ 2 according to the Edmonton Obesity Staging System (EOSS)\n* and at least one obesity-related comorbidity, including type 2 diabetes, steatohepatitis associated with metabolic dysfunction (MASH), polycystic ovary syndrome or osteoarthritis\n* speaking and understanding French\n* having access to the Internet\n\nExclusion Criteria:\n\n* inability to provide informed consent or to respond to questionnaires.","ALL","80 Years",{"count":70,"type":21},42,[24],"The goal of this observational study is to learn about the acceptability and feasibility of a therapeutic patient education program in adults living with an obesity. The main question it aims to answer is:\n\nIs the intervention of therapeutic patient education acceptable for patients living with an obesity?\n\nParticipants will answer questionnaires and participate to focus groups before and up to nine months after the intervention.",[74],"Obesity (BMI>30)",[76,77,78,79,80,81,82],"Obesity","Therapeutic patient education","type 2 diabetes","Metabolic disorders","empowerment","self-care skills","psycho-social skills","NOT_YET_RECRUITING","2026-06-23",{"date":86,"type":50},"2026-06-25",{"date":88,"type":21},"2026-07",{"date":90,"type":21},"2027-12",{"name":56,"class":57},1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":92},"100598156","self-questionnaire-in-osteoporosis-100598156","NCT07067827","Self-questionnaire in Osteoporosis","Clinical Validation of a Self-questionnaire in Adults With Osteoporosis","Inclusion Criteria:\n\n* Adult over 18\n* Followed by the rheumatology or endocrinology clinics at the CHUL (CHU de Quebec-Universite Laval)\n* Suffer from osteoporosis\n* Have internet access\n\nExclusion Criteria:\n\n* Unfit, unable to consent, unable to answer a questionnaire, unknown family history (e.g. adopted person)",{"count":101,"type":21},58,"OBSERVATIONAL","Osteoporosis is a multifactorial disease in which genetic predispositions play a key role in its development. A better understanding of family history and clinical manifestations among first- and second-degree relatives can help improve early detection and personalized care for at-risk patients. To this end, we will test a self-administered questionnaire previously developed by our research team. This questionnaire includes the main manifestations associated with rare genetic bone diseases such as osteogenesis imperfecta, hypophosphatasia, and osteopetrosis.",[105],"Osteoporosis",[107,108,109,110],"osteoporosis","self-administered questionnaire","family history","rare genetic bone diseases","2026-05-05",{"date":113,"type":50},"2026-05-08",{"date":115,"type":50},"2026-04-01",{"date":117,"type":21},"2027-12-31",{"name":56,"class":57},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":58},"100633374","acceptability-of-a-nurse-led-telehealth-remote-self-monitoring-model-of-care-in-patients-with-rheumatoid-arthritis-100633374","NCT07525856","Acceptability of a Nurse-led Telehealth Remote Self-monitoring Model of Care in Patients With Rheumatoid Arthritis","Acceptability of a Nurse-led Telehealth Remote Self-monitoring Model of Care in Patients With Rheumatoid Arthritis, a Multicentre Randomized Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of rheumatoid arthritis (RA) according to the ACR 2010 criteria\n* Disease duration ≥ six months\n* Who experienced a flare defined by an increase of the clinical disease activity index (CDAI) ≥ 4.5 or a DMARDs switch or addition within the preceding three months\n* Understanding French or English\n\nExclusion Criteria:\n\n* Inability to consent\n* Inability to complete questionnaires\n* No Internet access",{"count":127,"type":21},104,[24],"Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology.\n\nThe investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable.\n\nThis new approach involves nurses helping patients check their own health from home using an online platform.\n\n104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages.\n\nThis new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.",[131],"Rheumatoid Arthritis (RA)",[133,134,135,136,137,138],"Arthritis activity remote self-monitoring","Nurse-led telehealth intervention","Pilot randomised trial","Self-assessment of disease activity","RE-AIM implementation framework","Semi-structured interviews","2026-04-07",{"date":141,"type":50},"2026-04-13",{"date":143,"type":21},"2026-05",{"date":90,"type":21},{"name":56,"class":57},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":153,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":92},"100578930","cognitive-behavioral-therapy-for-fear-of-cancer-recurrence-in-women-with-brca12-gene-100578930","NCT06817694","Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1\u002F2 Gene","CBT-FCRBRCA1\u002F2","Inclusion Criteria:\n\n* 1\\) Have completed primary treatment for breast or ovarian cancer (i.e., surgery, chemotherapy, and radiotherapy).\n* 2\\) Be known to carry a BRCA1\u002F2 pathogenic mutation.\n* 3\\) Have a clinical level of fear of cancer recurrence as defined by a score of 13 or more on the Fear of Cancer Recurrence Inventory severity subscale.\n* 4\\) Be at least 18 years of age.\n* 5\\) Be able to read, understand and express herself in French.\n\nExclusion Criteria:\n\n* 1\\) Have distant metastases (in the case of ovarian cancer, only stages IV and IIIC will be excluded).\n* 2\\) Be known to carry a BRCA1\u002F2 \"VUS\" mutation.\n* 3\\) Have a known cognitive disorder.\n* 4\\) Have a known severe psychological disorder (e.g., psychotic disorder, bipolar disorder, substance abuse or dependence disorder).\n* 5\\) Have already taken part in the original FCR group psychotherapy at the CHU de Québec.\n* 6\\) Women taking psychotropic medication are eligible, but only if the dosage has been stable for at least one month.","FEMALE",{"count":155,"type":21},250,[24],"The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors to the specific needs of women who are carriers of the BRCA1\u002F2 genetic mutation will reduce their levels of fear of cancer recurrence. The main questions this study aims to answer are:\n\n* Will the women who have received the adapted CBT be satisfied with it?\n* Will there be a significant difference in the women's fear of cancer recurrence and other variables (e.g., depression, anxiety, insomnia, fatigue, quality of life) between the comparison groups?\n* Will the effects of the adapted CBT hold over time?\n* What are the roles of different etiological mediating variables in the relationship between fear of cancer recurrence and the effects of the adapted CBT on the severity of fear of cancer recurrence?\n\nResearchers will compare the effects of the adapted CBT between the immediate condition and the waitlist condition.\n\nParticipants will be:\n\n* Either placed in the immediate condition or the waitlist condition (the participants in the waitlist condition will begin their therapy once the immediate group is done with theirs).\n* Taking part in a group CBT session online once a week for eleven weeks.\n* Completing questionnaires pre-intervention, post-intervention, 3 months post-intervention, and 6 months post-intervention.",[159,160,161],"Breast Cancer Susceptibility Gene (BRCA1) Mutation","BRCA2 Mutation","Fear of Cancer Recurrence",[163,164,165,166,167],"BRCA1 Mutation","BRCA 2 Mutation","Fear of cancer recurrence","Cognitive-Behavioral Therapy","Cancer","2026-03-26",{"date":170,"type":50},"2026-03-31",{"date":172,"type":21},"2026-02",{"date":174,"type":21},"2028-12",{"name":56,"class":57},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":67,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":189,"conditions":190,"keywords":194,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":92},"100607790","phase-1-gmeb-sass-a-gene-modified-skin-substitute-for-rdeb-treatment-100607790","NCT07193134","GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment","Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) to Treat Patients Suffering From Recessive Dystrophic Epidermolysis Bullosa (RDEB)","Inclusion Criteria:\n\n* Age\n\nLearning phase:\n\n* Subjects 1 to 3: Eighteen (18) years old or older.\n* Subjects 4 to 6: Twelve (12) years old or older.\n* Subjects 7 to 9: Seven (7) years old or older.\n\nOther Inclusion Criteria:\n\n* Clinical diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) with confirmed biallelic pathogenic variant in the COL7A1 gene.\n* Candidates - or their parents\u002Fcaregivers if the candidates have limited comprehension, who are able to understand the study and to comply with the study procedures.\n* On the day of grafting, one or more blistered and\u002For erosive skin areas on the trunk and\u002For extremities large enough to graft at least three 25 to 50 cm2 GMEB-SASS grafts.\n* Ability to undergo anesthesia.\n\nExclusion Criteria:\n\n* Medical instability limiting the ability to travel to the investigative center.\n* Any medical condition or illness that may impact study participation or compromise the safety of the participants, as per the investigator's judgment.\n* Evidence of systemic infection.\n* Current evidence or a history of non-metastatic or metastatic squamous cell carcinoma at the site to be grafted.\n* Any clinically significant abnormal laboratory values or abnormal findings identified during physical examination or through medical history that could compromise participant safety, as per the investigator's judgment.\n* History of or known allergy to bovine proteins.\n* Active drug or alcohol addiction.\n* Female candidate who are pregnant or breast-feeding.\n* Candidate who has received immunotherapy, including oral corticosteroids (Prednisolone \\> 1 mg\u002Fkg), for more than one week, within 2 weeks prior to the study intervention (initial biopsy and GMEB-SASS grafting) (intranasal and topical preparations are permitted).\n* Candidate who has received chemotherapy within 60 days prior to the study intervention (initial biopsy and GMEB-SASS grafting).\n* Candidate who has received, in the last 6 months prior to the study intervention (initial biopsy and GMEB-SASS grafting), any gene therapy, chemical or biological product modifying collagen 7 expression.","7 Years",{"count":185,"type":21},9,[187,188],"PHASE1","PHASE2","This study is being done to find out if a new type of skin graft, called GMEB-SASS, is safe and effective for helping wounds heal in people with RDEB (Recessive Dystrophic Epidermolysis Bullosa).\n\nThe GMEB-SASS graft contains two types of living skin cells: keratinocytes and fibroblasts. It is made in a laboratory using a small sample of the patient's own skin.\n\nTo help the patient's skin cells produce a missing protein called type VII collagen, scientists grow the patient's cells in the lab and use a virus-like tool (called a retroviral vector) to give the cells the correct instructions. This allows the cells to make the normal protein that is missing in people with RDEB.\n\nThe graft is designed to be permanent, and the goal is to improve wound healing by replacing damaged skin cells with healthy ones.",[191,192,193],"RDEB","Recessive Dystrophic Epidermolysis Bullosa","Epidermolysis Bullosa Dystrophica, Recessive",[195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210],"Skin Abnormalities","Congenital Abnormalities","Epidermolysis Bullosa","Skin Diseases, Genetic","Genetic Diseases, Inborn","Collagen Diseases","Connective Tissue Diseases","Skin and Connective Tissue Diseases","Skin Diseases","Skin Diseases, Vesiculobullous","Epidermolysis Bullosa Dystrophica","Genetic therapy","Autologous Skin Graft","SIN Retroviral Vector","Type VII Collagen","COL7A1","2026-03-17",{"date":213,"type":50},"2026-03-18",{"date":215,"type":50},"2026-01-07",{"date":217,"type":21},"2035-12",{"name":56,"class":57},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":153,"minAge":18,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":92},"100537317","paravertebral-block-for-mastectomy-with-immediate-reconstruction-100537317","NCT06276257","Paravertebral Block for Mastectomy With Immediate Reconstruction","Comparison Between Paravertebral Block and Usual Analgesia in Patients Undergoing Unilateral Total Mastectomy With Immediate Reconstruction","Inclusion Criteria:\n\n* 18-70 years of age\n* woman scheduled for unilateral mastectomy with immediate reconstruction\n\nExclusion Criteria:\n\n* Patients who will have an axillary dissection during surgery.\n* Woman with severe hepatic insufficiency (Child Pugh Classification B and above24).\n* Woman with kidney failure stage 4 and above25.\n* Body mass index (BMI) \\> 40 kg\u002Fm2.\n* Woman with an allergy to local anesthetics.\n* Woman with a bleeding disorder in whom BPV is contraindicated.\n* Woman in whom stopping antiplatelet or anticoagulant therapy does not allow compliance with the standards of practice of neuraxial anesthesia issued by the American Society of Regional Anesthesia.\n* Woman with a single lung.\n* Pregnant woman.","70 Years",{"count":228,"type":21},60,[24],"Following a mastectomy, patients may develop chronic pain, called post-mastectomy pain syndrome (PMPS). This syndrome manifests itself as complex neuropathic pain that seems linked to nerve damage suffered either during surgery, during healing or by nervous system dysfunction. However, the exact pathophysiology remains unknown. Typically, the pain is located on the ipsilateral side of the surgery and projects to the anterior thorax to the lateral thorax and may affect the proximal part of the arm. This pain persists for more than three months following the procedure and has the characteristics of neuropathic pain: burning sensation, tingling, electric shock, hyperalgesia, etc. The prevalence of PMDS varies between 2% and 78%; this disparity comes from the fact that there are no clear criteria in the literature for making the diagnosis. One of the risk factors for developing PMDS is the presence of acute pain immediately postoperatively.\n\nThe main objective of this study is to compare two analgesic modalities, namely BPV (study modality) and usual analgesia (control modality), in patients undergoing total mastectomy with immediate reconstruction under general anesthesia with the aim of to evaluate their functional pain score at 24, 48 and 72 hours following the surgical procedure.",[232],"Postoperative Pain",{"date":234,"type":50},"2026-03-19",{"date":236,"type":50},"2024-08-05",{"date":238,"type":21},"2026-12",{"name":56,"class":57},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":92},"100546812","impact-of-capillaroscopy-on-the-management-of-undifferentiated-connective-tissue-disease-100546812","NCT06399822","Impact of Capillaroscopy on the Management of Undifferentiated Connective Tissue Disease","Impact of Capillaroscopy on the Management of Undifferentiated Connective Tissue Disease: a Randomized Pilot Clinical Study","Inclusion Criteria:\n\n* Be aged 18 and over;\n* Have been diagnosed with undifferentiated connective tissue disease by a rheumatologist;\n* Meet the preliminary classification criteria for undifferentiated connective tissue disease: present signs and symptoms suggestive of connective tissue disease, but do not meet the criteria for a connective tissue disease and have a positive antinuclear antibody on at least 2 occasions;\n* Have developed the first signs and symptoms of the disease less than 10 years before recruitment.\n\nExclusion Criteria:\n\n* In the opinion of the clinician, have a health condition that does not allow a delay of six months before carrying out the capillaroscopy;\n* Have been diagnosed and\u002For meet the classification criteria for another connective tissue disease (for example, systemic lupus, etc.);\n* Have already performed a capillaroscopy in the past, regardless of the time or the reason;\n* Be unable to consent or respond to questionnaires.",{"count":248,"type":21},40,[24],"Connective tissue diseases (CTD) are a group of diseases with diverse manifestations, most often multisystemic, which share an autoimmune etiology. They include Systemic lupus erythematosus (SLE), Systemic sclerosis (SSc), Sjögren's syndrome (SS), Inflammatory myopathies (IM) and Mixed connective tissue disease (MCTD).\n\nMany patients in rheumatology present signs and symptoms of CTD, but without meeting all the classification criteria for one of these diseases. These patients will generally receive a diagnosis of undifferentiated connective tissue disease (UCTD). It is increasingly suggested that there are two subgroups of patients with UCTD: one which will eventually evolve into a better characterized CTD (approximately 30% of patients at 5 years) and another with a more benign prognosis. The optimal management of patients with UCTD is not clearly established.\n\nCapillaroscopy is a diagnostic test used in the investigation of patients with CTD. It is a low-cost, non-invasive, rapid and specific test in the evaluation of this class of diseases. Its role is now well established in the diagnosis of SSc and in the investigation of Raynaud's phenomenon. In addition, capillaroscopy helps to identify patients suffering from CTD more quickly.\n\nKnowledge about the role of capillaroscopy in UCTD is more limited. It is established that a significant proportion of patients with UCTD present abnormalities on UCTD present non-specific abnormalities and 11% present a scleroderma pattern. In these patients, abnormal capillaroscopy seems to increase the risk of progressing to a better characterized CTD, notably SSc.\n\nHowever, although capillaroscopy is increasingly used in rheumatology in patients with CTD, more research is needed to clarify the role of this examination in UCTD. First, it is not established whether capillaroscopy should be performed in all patients with UCTD, nor when exactly it should be performed. There also remain questions about the impact of capillaroscopy on the prognosis and management of patients with this disease. To our knowledge, there is no prospective study that has addressed this question. The investigators hypothesize that in patients with UCTD, capillaroscopy compared to usual care makes it possible to increase the proportion of patients obtaining a diagnosis of better characterized CTD in the first six months of follow-up.",[252],"Undifferentiated Connective Tissue Diseases",[254,255,256],"undifferentiated connective tissue disease","capillaroscopy","randomized pilot clinical study","2026-03-16",{"date":211,"type":50},{"date":260,"type":50},"2024-05-22",{"date":90,"type":21},{"name":56,"class":57},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":92},"100520139","a-trial-evaluating-toxicity-of-sbrt-and-ldrb-in-localized-prostate-cancer-100520139","NCT06052683","A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.","A Randomized Trial Evaluating Toxicity of Stereotactic Body Radiotherapy (SBRT) and Low-dose Rate Brachytherapy (LDRB) in Localized Prostate Cancer.","Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 8 months. Patients on active surveillance with evidence of disease progression are eligible to the protocol as long as they meet the eligibility criteria and have a recent prostate biopsy (within 8 months).\n* Low-risk and favourable intermediate-risk prostate cancer patients are eligible according to the following definitions:\n\nLow-risk disease defined as: Clinical stage T1-T2a and Gleason 6 and PSA ≤ 10 ng\u002FmL\n\nFavourable intermediate-risk cancer defined by a single NCCN intermediate risk factor:\n\n\\[NCCN : National Comprehensive Cancer Network\\]\n\n1. Clinical stage T2b\n2. PSA \\> 10 but ≤ 20 ng\u002FmL\n3. Gleason 7 (3+4)\n\nLymph node evaluation by either computed tomography (CT) or magnetic resonance imaging (MRI) is optional and is left at the discretion of the treating physician.\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group performance status 0-1\n* Patient considered medically fit for LDR brachytherapy\n* Prostate volume ≤ 60 cc, measured by Trans-Rectal UltraSound (TRUS), CT or MRI, within the last 6 months.\n* International Prostate Symptom Score (IPSS) ≤ 20 (alpha blockers allowed)\n* No alpha reductase inhibitors use within two weeks of randomization\n* No hormonal therapy is accepted\n* Patients must provide a study-specified informed consent form prior to study entry.\n* Patients must be willing and able to complete the EPIC-26, IPSS and SHIM questionnaires.\n\n\\[EPIC-26: Expanded Prostate Cancer Index Composite score ; SHIM: Sexual Health Inventory for Men questionnaire\\].\n\nExclusion Criteria:\n\n* Clinical or radiological evidence of metastatic disease or nodal involvement.\n* Clinical stage ≥ T2b.\n* Gleason score ≥ 4 + 3.\n* Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 3 years.\n* Prior radical surgery for carcinoma of the prostate, or prior TURP (Trans-Urethral Resection of the Prostate).\n* Prior pelvic radiotherapy or prior radiotherapy that would result in overlap of radiation fields.\n* Prior chemotherapy for prostate cancer, or prior chemotherapy within the last 3 years.\n* Prior cryosurgery of the prostate.\n* Prior or current bleeding diathesis making fiducial placement or brachytherapy procedure unsafe.\n* Previous androgen deprivation therapy within 6 months of the registration.\n* Bilateral hip prostheses\n* Any severe active comorbidity, laboratory abnormality, psychiatric illnesses, active or uncontrolled infections, serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision). Such examples includes active inflammatory bowel disease, significant urinary symptoms,",{"count":271,"type":21},208,[24],"The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer. The two main questions it aims to answer are :\n\n1. Does SBRT (Stereotactic Body RadioTherapy) for low and intermediate risk prostate cancer patients will result in less genito-urinary (GU) and gastro-intestinal (GI) toxicities than LDRB (Low-Dose Rate Brachytherapy)?\n2. Does prostate cancer patients treated by SBRT have a better quality of life than patients treated by LDRB\n\nNo randomized trial has yet compared LDRB to SBRT head to head.",[29],[276,277],"Low-dose rate brachytherapy (LDRB)","Stereotactic Body RadioTherapy (SBRT)","2026-02-16",{"date":280,"type":50},"2026-02-17",{"date":282,"type":50},"2019-09-30",{"date":284,"type":21},"2029-09-30",{"name":56,"class":57},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":307,"leadSponsor":309,"locationsCount":92},"100600173","phase-4-immunoglobulins-in-multiple-myeloma-patients-receiving-a-bcma-directed-t-cell-engager-100600173","NCT07094048","Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager","CHUQUL_HO001","Inclusion Criteria:\n\n* Multiple myeloma patient:\n* ≥ 18 years old\n* ≥ 1 prior lines of therapy\n* Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)\n* On previous Ig support or not\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Pregancy or breastfeeding",{"count":294,"type":21},80,[296],"PHASE4","Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.",[299,300],"Multiple Myeloma Refractory","Relapsed Multiple Myeloma",[302,303],"Immunoglobulins","Multiple Myeloma","2026-01-05",{"date":215,"type":50},{"date":304,"type":50},{"date":308,"type":21},"2029-12",{"name":56,"class":57},{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":336},"100464434","phase-2-a-phase-ii-trial-of-bicalutamide-in-patients-receiving-intravesical-bcg-for-non-muscle-invasive-bladder-cancer-100464434","NCT05327647","A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer","A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer","BicaBCa","Inclusion Criteria:\n\n1. Males, age 18 or greater.\n2. Patients with histologically confirmed non-muscle invasive urothelial carcinoma.\n3. Patients have been recommended for a course of intravesical BCG induction treatment by their urologist\n4. Patients who received gemcitabine, epirubicin or mitomycin C instillations immediately post-operatively will be eligible for enrollment.\n5. Patients with partners of child-bearing potential must agree to 2 acceptable forms of birth control and be continued for at least 3 months after study drug is discontinued.\n\nExclusion Criteria:\n\n1. Patients who have received induction BCG therapy within the last 5 years will be ineligible for enrolment.\n2. Patients with a history of myocardial infarction or hospital admission for heart failure within the previous 12 months or who have unstable cardiovascular status will be ineligible for enrolment.\n3. Patients who have uncontrolled hypertension (for our purposes, defined as those having a systolic blood pressure \\> 160 documented on 2 occasions despite appropriate medical therapy) will similarly be ineligible.\n4. Patients with a history of liver disease whose hepatic enzymes, alkaline phosphatase or bilirubin are greater than twice the upper limit of normal will be ineligible.\n5. Patients with clinical hypogonadism, those on androgen replacement therapy, or those with prostate cancer or other diseases treated with systemic hormonal therapy will be ineligible for study enrolment. Patients receiving 5ARIs will not be excluded.\n6. Patients who have cancer treatment ongoing or planned in the near future which can be anticipated to decrease their 2-year survival or BCa treatment plan will be ineligible.\n7. Patients taking an investigational drug within 2 weeks of enrolment into this study will be ineligible.\n8. Patients receiving or planning to receive coumadin therapy will be ineligible.",{"count":319,"type":21},160,[188],"This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.",[323],"Non-Muscle Invasive Bladder Cancer",[325,326,327],"Bicalutamide","BCG instillation","Placebo","2025-12-17",{"date":330,"type":50},"2025-12-18",{"date":332,"type":50},"2022-06-23",{"date":334,"type":21},"2026-12-31",{"name":56,"class":57},7,{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":345,"sex":17,"minAge":18,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":357,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":92},"100499706","ultra-hypofractionnated-radiotherapy-with-hdr-brachytherapy-boost-100499706","NCT05786742","Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.","ULTRA-HYPO Fractionated (UHF) Compared to Moderate-HYPO Fractionated (MHF) Prostate IGRT With HDR Brachytherapy BOOST : A Phase 1-2 Study.","HYPO-5","Inclusion Criteria:\n\n* Biopsy proven Prostate adenocarcinoma\n* Stage T1c, T2 (Annex 2)\n* Stage Nx or N0\n* Stage Mx or M0\n* PSA \\\u003C 20ng\u002Fml\n* Gleason Score 6 or 7\n* Having the ability to sing a written consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18ans\n* Clinical Stage T3 or T4\n* Stage N1\n* Stage M1\n* PSA \\> 20\n* Gleason Score 8 to 10\n* IPSS Score \\> 20 alpha-blocking medication.\n* Prior pelvic radiotherapy.\n* History of active collagenosis (Lupus, Sclerodermia, Dermatomyosis)\n* Past history of Inflammatory Bowell Disease\n* Bilateral hip prosthesis",true,"95 Years",{"count":348,"type":21},205,[24],"Phase 1-2 study, comparing ultra-hypofractionnated (UH) to a moderately hypofractionnated (MH) radiation therapy, with image guided HDR prostate brachytherapy. Using iso-equivalent doses, a non-inferiority analysis will be done in order to prove UH non-inferior to MH, toxicity wise. Acceptability, tolerability, acute and late toxicity will be reported. MRI visible dominant intra-prostatic lesion will be outlines and variability between radiation oncologists and radiologists will be reported. As secondary objective, biochemical and clinical failure free survival will be reported at 5 \\& 10 years.",[29,352,353,354,355,356],"Radiotherapy Side Effect","Hypofractionation","Brachytherapy","Radiotherapy","Localized Prostate Carcinoma",[358,359,360],"hypo fractionation","brachytherapy","Ultra Hypo fractionation","2025-09-07",{"date":363,"type":50},"2025-09-09",{"date":365,"type":50},"2014-04",{"date":367,"type":21},"2033-12",{"name":56,"class":57},{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":67,"minAge":4,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":336},"100235998","phase-1-sass-2--self-assembled-skin-substitute-for-the-autologous-treatment-of-severe-burn-wounds-in-acute-stage-of-burn-trauma-100235998","NCT02350205","SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma","SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma.","Inclusion Criteria:\n\n* Deep second degree burns or third degree burns over 50% TBSA (Total body surface area) at time of recruitment or as determined by the surgeon;\n* Limited availability of donor sites for autografts;\n* Consent obtained by the participant or by the appropriate representative in case of inapt prospective participants or minors.\n\nExclusion Criteria:\n\n* Skin grafting needed only on the face, hands, feet, ears or genital area;\n* Connective tissue diseases;\n* Hypersensitivity to bovine proteins;\n* Coagulation disorders prior being burned;\n* Immunodeficiency prior being burned;\n* Uncontrolled diabetes prior being burned;\n* Permanent wound coverage before SASS grafts are ready;",{"count":377,"type":21},52,[187,188],"This clinical trial is designed to assess the safety, effectiveness and benefits of Self Assembled Skin Substitute SASS grafts as a permanent skin replacement for the treatment of full-thickness burn wounds that require permanent coverage where the availability of donor sites is limited.",[381],"Burns",[383,381,384],"Burn wounds","Skin substitute","2025-07-22",{"date":387,"type":50},"2025-07-25",{"date":389,"type":50},"2015-12",{"date":391,"type":21},"2029-01",{"name":56,"class":57},{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":67,"minAge":401,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":414,"locationsCount":58},"100190563","autologous-cultured-corneal-epithelium-ceca-for-the-treatment-of-limbal-stem-cell-deficiency-100190563","NCT01756365","Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency","Autologous Cultured Corneal Epithelium ( Culture d'épithélium cornéen Autologue CECA) for the Treatment of Unilateral Corneal Lesions Associated With Limbal Stem Cell Deficiency","CECA","Inclusion Criteria:\n\nAll genders\n\n* Adults\n* Minors\n* LSCD in one or two eyes. A minimum of 1-3 mm2 of undamaged limbus is required for a biopsy to be taken without foreseeable adverse consequences for the donor eye\n\nExclusion Criteria:\n\n* Donor eye not sufficiently healthy to allow for the harvesting of a 1-3 mm2 limbal biopsy without foreseeable consequences for the donor eye\n* Pregnancy\n* Breast-feeding\n* Incapacitated person\n* known allergy to aprotinine (Trasylol (R))\n* Hypersensibility to bovine proteins","1 Year",{"count":403,"type":21},54,[24],"The study \" Autologous cultured corneal epithelium (CECA) for the treatment of corneal lesions associated with limbal stem cell deficiency\" is the first clinical trial of this product manufactured at the LOEX laboratory. The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency. The study is a phase I\u002Fphase II study with the goal to evaluate safety and efficacy of the CECA graft for the treatment of human patients suffering from limbal stem cell deficiency.\n\nThe trial is open to all genders. The inclusion of 5 minors is planned.",[407],"Limbal Stem Cell Deficiency","2025-07-07",{"date":410,"type":50},"2025-07-10",{"date":412,"type":4},"2012-12",{"date":90,"type":21},{"name":56,"class":57},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":424,"studyType":102,"phases":4,"briefSummary":425,"conditions":426,"keywords":431,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":92},"100558161","bone-and-muscle-health-following-sleeve-gastrectomy-in-men-premenopausal-and-postmenopausal-women-100558161","NCT06547515","Bone and Muscle Health Following Sleeve Gastrectomy in Men, Premenopausal and Postmenopausal Women","BONUS","Inclusion Criteria:\n\n* Men and women aged \\>18 years;\n* Awaiting SG for the bariatric group or meeting the criteria for SG but not undergoing surgery for the non-surgical group.\n* Menopause: defined as the absence of menses for a year and a serum follicular-stimulating hormone (FSH) \\>40 UI\u002FL.\n* Women taking oral contraceptive pills or hormone replacement therapy\n* Patients with type 2 diabetes.\n\nExclusion Criteria:\n\n* Type 1 diabetes;\n* Disease (e.g., uncontrolled thyroid disease, Malabsorptive or overt inflammatory disorder)\n* Metabolic bone disease other than osteoporosis or type 2 diabetes,\n* Creatinine clearance \\\u003C30 ml\u002Fmin) or medication (e.g., glucocorticoids, anti-epileptic drugs, osteoporosis therapy, thiazolidinediones) affecting bone metabolism;\n* Weight \\>204 kg (DXA weight limit) or BMI \\>60 kg\u002Fm2 (upper limit to allow for QCT examination);\n* Current or planned pregnancy during follow-up; breast-feeding.",{"count":423,"type":21},156,"36 Months","Background: Bariatric surgery is gaining in popularity. While it's health benefits are undisputed, the older malabsorptive bariatric procedures (Roux-in-Y gastric bypass - RYGB and biliopancreatic diversion - BPD) are associated with an increased risk of fractures and falls as early as 3-5 years after surgery. Sleeve gastrectomy - SG is now the most performed bariatric procedure. Although SG does not cause malabsorption, it is predicted to result in bone and muscle loss via weight loss and weight loss-independent mechanisms. Primary aim: to compare the changes in spine volumetric bone mineral density (vBMD) by quantitative computed tomography (QCT) and muscle mass at mid-femur by computed tomography (CT) at 3 years in the 3 groups of: 1) men; 2) premenopausal women; 3) postmenopausal women after SG versus their respective non-surgical peers who did not undergo SG in the 3-year period following recruitment. Secondary aims: to compare the changes in vBMD by QCT at skeletal sites other than the spine and in areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry (DXA), whole-body muscle mass by DXA, muscle quality by CT at mid-femur and muscle strength as well as in selected physical performance and capacity tests shown to predict falls and fractures between 0-1 and 1-3 years after SG in the same 3 groups after SG vs. in the respective non-surgical groups.",[427,428,429,430],"Bariatric Surgery","Bone Health","Severe Obesity","Muscle Health",[432,433,429,430],"bariatric surgery","Bone health","2025-06-05",{"date":436,"type":50},"2025-06-10",{"date":438,"type":50},"2022-09-14",{"date":440,"type":21},"2026-08-15",{"name":56,"class":57},{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":345,"sex":67,"minAge":18,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":462},"100320748","bone-health-after-bariatric-surgery-in-patients-with-type-2-diabetes-100320748","NCT03455868","Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes","BODI","Inclusion Criteria:\n\n* bariatric groups: men and women; 18 to 60 years old; with a BMI \\>=35 kg\u002Fm2; with type 2 diabetes: use of oral hypoglycemic agents or insulin OR 2 of the following tests confirming type 2 diabetes: HbA1c \\>=6.5%; fasting glucose \\>=7.0 mM; 2-h glucose post 75g oral glucose tolerance test (OGTT) \\>=11.1 mM) (guidelines.diabetes.ca);) or without diabetes: HbA1c \\\u003C6.5% AND fasting glucose \\\u003C7.0 mM; who are awaiting bariatric surgery. Control group: BMI 25.0 to 29.9 kg\u002Fm2 (overweight group); without diabetes or prediabetes: HbA1c \\\u003C6.0% AND fasting glucose \\\u003C6.1 mM (Diabetes Canada criteria), with a stable weight for the last 3 months.\n\nExclusion Criteria:\n\n* bariatric groups: type 1 diabetes; disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder, metabolic bone disease, creatinine clearance \\\u003C60 ml\u002Fmin) or medication (e.g. glucocorticoids, anti-epileptic drugs, osteoporosis therapy and thiazolidinediones) affecting bone metabolism; BMI\\>60 kg\u002Fm2; CT scan impossible to perform (e.g. patient too large for the gantry aperture); pregnant women or women who plan to become pregnant during the study or women of childbearing age who do not agree to take an appropriate contraceptive method during the study; history of oesophageal, gastric or digestive surgery; history of bariatric surgery; cancer at risk of recurrence during the study; Prosthesis that could interfere with interpretation of imaging data; Chronic severe condition or illness precluding from participation in the project.\n\nControl group: Same criteria plus: \\>5% change in weight in the last 3 months; pregnancy or lactation in the last year.","60 Years",{"count":451,"type":21},100,"Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate the impact of the most popular bariatric procedure worldwide (sleeve gastrectomy (SG)) on vBMD by QCT in patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after bariatric surgery in patients with type 2 diabetes; (2) to compare vBMD and its potential determinants after bariatric surgery with obese controls without diabetes as well as with controls without obesity and normoglycemia.",[427,428,454,455],"Obesity, Morbid","Diabetes Mellitus, Type 2",{"date":436,"type":50},{"date":458,"type":50},"2018-03-15",{"date":460,"type":21},"2025-12-01",{"name":56,"class":57},3,{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":473,"briefSummary":474,"conditions":475,"keywords":478,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":4},"100508128","phase-1-a-phase-12-study-of-personalized-psma-radiopharmaceutical-therapy-100508128","NCT05896371","A Phase 1\u002F2 Study of Personalized PSMA Radiopharmaceutical Therapy","PROstate-specific Membrane Antigen DosImetry-Guided EndoradiotherapY: a Phase 1\u002F2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)","PRODIGY-1","Inclusion Criteria:\n\n* \\>18 y.o. adults able to provide consent\n* Inoperable or metastatic PSMA-expressing cancer, with significant PSMA expression defined as uptake in at least one lesion that is superior to that of the liver on PSMA positron-emission tomography (PET) within 3 months prior to enrolment\n* Cancer progression documented within 3 months prior to enrolment as per the investigator's assessment, without initiation of another anti-cancer treatment since (excluding palliative radiation therapy to a minority of the tumor burden), unless that anti-cancer treatment was stopped prematurely because of intolerance\n* For participants with a cancer other than mCRPC, a recommendation from a multidisciplinary tumor board (MDT) in favor of PSMA RPT must be obtained\n\nExclusion Criteria:\n\n* Platelets \\\u003C 50 x 106\u002FL\n* Absolute neutrophil count (ANC) \\\u003C 1.0 x 106\u002FL\n* Eastern Cooperative Oncology Group (ECOG) 4 or prognosis \\\u003C 3 months, for cancer-related or other serious medical conditions, as per investigator's assessment\n* Known presence of central nervous system metastasis at risk of complication, which cannot be adequately stabilized (e.g. radiotherapy or corticoid prophylaxis), as per investigator's assessment\n* Any condition that would limit the ability to comply with the study protocol, as per investigator's assessment\n* Pregnancy or breastfeeding (e.g. for female participants with non-prostate cancer)",{"count":472,"type":21},500,[187,188],"The goal of this clinical trial is to study a personalized regime of lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in patients with progressive and\u002For symptomatic, inoperable PSMA-expressing cancers of prostatic or other origins.\n\nThe main questions it aims to answer are:\n\n* To establish a dosimetry-based, personalized regime of 177Lu-PSMA\n* To report on the efficacy of personalized 177Lu-PSMA\n\nParticipants (stratified by risk factors of toxicity) will receive up to 6 cycles of a personalized activity of 177Lu-PSMA based on renal dosimetry. In the phase 1, the prescribed absorbed dose to the kidney will be escalated, to determine the regime that will be administered in the phase 2. The best response within 12 months after the first cycle will be assessed. Salvage treatment of 3 cycles may be offered to responders after re-progression.",[167,29,476,477],"Metastatic Cancer","Metastatic Prostate Cancer",[479,480,481,482,483],"Prostate-Specific Membrane Antigen","177Lu-PSMA","Radiopharmaceutical Therapy","Dosimetry","Personalized","2025-03-25",{"date":486,"type":50},"2025-03-30",{"date":488,"type":21},"2028-03",{"date":490,"type":21},"2034-03",{"name":56,"class":57},{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":22,"phases":501,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":516,"locationsCount":92},"100556266","evaluation-of-intraocular-pressure-following-a-vitreoretinal-surgery-using-goldmann-applanation-tonometry-icare-and-accupen-100556266","NCT06522867","Evaluation of Intraocular Pressure Following a Vitreoretinal Surgery Using Goldmann Applanation Tonometry, Icare and Accupen","Reliability Evaluation of Intraocular Pressure At Day 1 Following Vitreoretinal Surgery, Comparing Goldmann Applanation Tonometry (Gold Standard) to Icare and Accupen","Inclusion Criteria:\n\n* Age ≥ 18\n* Received a vitreoretinal surgery\n\nExclusion Criteria:\n\n* Corneal dystrophy\n* Corneal surgery (penetrating keratoplasty, DSAEK\u002FDMEK less than 6 months, radial keratotomy)\n* Irregular corneal surface\n* Active corneal ulcer\n* Active epithelial deficit\n* Central corneal scarring\n* A history of scleral buckle",{"count":500,"type":21},67,[24],"The goal of this prospective controlled study is to measure the reliability of two intraocular pressure (IOP)-measuring instruments in comparison to the gold standard, Goldmann applanation tonometry (GAT) following vitreo-retinal surgery. The main question the current study aims to answer is: are Icare and Accupen as accurate as GAT in measuring IOP one day post eye surgery?\n\nParticipants in this study will have their IOP measured by the three different instruments one day post-surgery.",[504],"Intraocular Pressure",[504,506,507,508,509],"Accupen","Icare","Goldmann","vitrectomy","2024-09-25",{"date":512,"type":50},"2024-09-26",{"date":236,"type":50},{"date":515,"type":21},"2027-08-01",{"name":56,"class":57},{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":530,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":92},"100425225","implementation-of-cbt-i-in-cancer-clinics-100425225","NCT04817163","Implementation of CBT-I in Cancer Clinics","Implementation of a Stepped Care Cognitive-Behavioral Therapy for Insomnia in Routine Cancer Care","Inclusion Criteria:\n\n* have received a diagnosis of non-metastatic cancer (any type)\n* to be aged 18 years and older\n* to be readily able to read and understand French or English\n* having the minimum cognitive abilities to read, understand and memorize information\n* having access to Internet\n\nExclusion Criteria:\n\n* having a psychological comorbidity needing clinical attention (e.g., major depressive disorder)\n* having severe cognitive impairments (e.g., diagnosis of Parkinson's disease, dementia)\n* having insomnia due to a temporary condition (e.g., acute pain, short-term medication side effects, environmental factors)",{"count":525,"type":21},120,[24],"Insomnia affects 30-60% of cancer patients, thus making it one of the most common disturbances in this population. When untreated, which is the rule rather than the exception, insomnia often becomes chronic. Chronic insomnia is associated with numerous negative consequences (e.g., increased risk for psychological disorders, health care costs). A large body of evidence supports the efficacy of cognitive-behavioral therapy for insomnia (CBT-I) in cancer patients, but CBT-I is still not offered routinely in cancer clinics. Self-administered CBT-I (e.g., video-based intervention) has been developed to increase patients' access to this treatment. However, results of clinical trials have suggested that these minimal treatments would be better used as a first step of a stepped care model. In stepped care, patients receive only the level of intervention they need. Generally, the entry level is a minimal, less costly, intervention (e.g., self-help intervention) followed by a more intensive form of treatment if needed (if the patient is still symptomatic). The investigators have recently assessed the efficacy of a stepped care model to administer CBT-I in cancer patients, which includes a web-based CBT-I (called Insomnet) followed by up to 3 sessions with a psychotherapist if the patient is still symptomatic. Results of this study suggest that this model of care is non-inferior to a standard face-to-face treatment (Savard, Ivers, et al., in revision), while being more cost-effective. A stepped care CBT-I could therefore be offered in routine cancer care clinics.\n\nThis project will assess the feasibility and effectiveness of implementing a stepped care CBT-I in real-world cancer clinics, using a non-randomized stepped wedge design to compare the effects of our program (active phase) with a passive phase. The program is called Insomnia in Patients with Cancer - Personalized Treatment (IMPACT). The stepped care CBT-I (active intervention) is being implemented sequentially in the four participating hospitals over a number of equally spaced time periods of 4 months (wedges), for a total of 5 time points, over a period of 20 months.",[529],"Insomnia",[529,167,531,532,533,534,535,536],"Cognitive-behavioral therapy","Stepped care model","Self-administered treatment","Web-based intervention","Implementation","Cost-effectiveness","2024-09-06",{"date":539,"type":50},"2024-09-19",{"date":541,"type":50},"2019-12-13",{"date":543,"type":21},"2025-05-30",{"name":56,"class":57},{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":22,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":92},"100304886","quality-of-life-related-to-different-treatment-protocols-for-post-thyroidectomy-hypoparathyroidism-100304886","NCT03249012","Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism","Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism","Inclusion Criteria:\n\n* Total thyroidectomy or completion hemithyroidectomy\n\nExclusion Criteria:\n\n* Need for neck dissection\n* Unable to fill in questionnaires (intellectual deficit, severe psychiatric disorder, illiterate, does not speak French or English)",{"count":525,"type":21},[24],"This study aims to compare two different protocols commonly used in the management of post thyroidectomy hypoparathyroidism : PTH based calcium repletion and empiric repletion. The investigators aim to compare the quality of life associated with these two protocols in a randomized trial.",[556,41],"Hypoparathyroidism Postprocedural","2024-08-26",{"date":559,"type":50},"2024-08-28",{"date":561,"type":50},"2017-09-01",{"date":563,"type":21},"2025-09-01",{"name":56,"class":57},{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":22,"phases":575,"briefSummary":576,"conditions":577,"keywords":580,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":92},"100507416","pilot-study-of-pacha-program-to-enhance-adherence-to-adjuvant-endocrine-therapy-among-breast-cancer-survivors-100507416","NCT05887102","Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors","Pilot Study of a Community Pharmacy-Based Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors","PACHA","Inclusion Criteria:\n\nFor pharmacies :\n\n* In the province of Quebec, Canada\n* At least one pharmacist agrees to take charge of the project in their pharmacy\n* At least one women has initiated adjuvant endocrine therapy (AET) in the last 6 months in the pharmacy\n\nFor pharmacists :\n\n* Practicing in a pharmacy in the province of Quebec\n* Provide consent\n\nFor women :\n\n* 18 years old or older\n* Were diagnosed with a first non-metastatic, hormone-sensitive breast cancer\n* Received and AET prescription for the first time in the last 6 months\n* Are fluent in French\n* Have internet access\n* Provide consent\n\nExclusion Criteria:\n\nFor women :\n\n• Live in a residential facility where AET is not self-managed",{"count":574,"type":21},66,[24],"The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer. PACHA (programme en Pharmacie pour l'ACcompagnement des femmes ayant de l'Hormonothérapie Adjuvante) is a community pharmacy-based program aimed at optimizing the experience of AET and its use. The main questions it aims to answer are :\n\n* Does the program have an effect on factors expected to influence AET adherence?\n* Is the program acceptable?\n* Is the implementation of the program feasible?\n* What is the feasibility of procedures for carrying out a full-scale study?\n\nParticipating community pharmacies will be randomized. Pharmacists working in pharmacies assigned to the PACHA group (33 pharmacies) will receive web-based training and manuals to use during their consultations with women having an AET. Recruited women attending these pharmacies will also have access to information and resources about AET (videos, evidence-based booklet). Pharmacists practicing in pharmacies assigned to the control group (33 pharmacies) will provide usual care.",[578,579],"Breast Neoplasms","Breast Cancer",[579,581,582,583,584,585,586,587,588,589,590],"Adjuvant Endocrine Therapy","Adherence to Treatment","Community Pharmacy","Support","Survivorship","Intervention Evaluation","Pilot Study","Randomized Controlled Trial","Feasibility Study","Mixed-Methods","2024-08-20",{"date":593,"type":50},"2024-08-22",{"date":595,"type":50},"2023-06-07",{"date":597,"type":21},"2025-03",{"name":56,"class":57},{"id":600,"slug":601,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":11,"sex":67,"minAge":606,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":22,"phases":609,"briefSummary":610,"conditions":611,"keywords":613,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":626,"locationsCount":627},"100430800","gps-project-evaluation-of-the-impact-of-the-reorganization-of-work-into-a-family-medicine-group-on-pharmacotherapy-and-support-for-the-autonomy-of-seniors-with-major-neurocognitive-disorders-100430800","NCT04889794","GPS Project Evaluation of the Impact of the Reorganization of Work Into a Family Medicine Group on Pharmacotherapy and Support for the Autonomy of Seniors With Major Neurocognitive Disorders","GPS Project - Evaluation of the Impact of the Reorganization of Work Into a Family Medicine Group on Pharmacotherapy and Support for the Autonomy of Seniors With Major Neurocognitive Disorders","Inclusion Criteria:\n\n* All seniors (65 years of age or older) undergoing cognitive evaluation OR referred to a memory clinic OR having been diagnosed with cognitive impairment within the last year OR with MCND and followed up at home AND,\n* referred to the pharmacist, for the FMGs exposed\n* taking prescription medications\n\nExclusion Criteria:\n\n* Seniors in palliative care OR\n* unable to answer questionnaires in French AND without a caregiver.","65 Years",{"count":608,"type":21},400,[24],"The model of care tested in the GPS project aims to optimize pharmacotherapy for seniors undergoing cognitive assessment or suffering from major neurocognitive disorder (MCND) at home. The goal is to reduce polymedication, inappropriate medications and the treatment burden of seniors and to maintain their cognitive health, quality of life and autonomy. The intervention will include knowledge exchange sessions with nurses, pharmacists, and doctors in FMGs, and increased collaboration between these professionals and home care services teams. Other goal is to increase the satisfaction of the seniors, their families, and the professionals involved in the GPS project.",[612],"Major Neurocognitive Disorder",[614,615,616,617,618,619,620,621],"living lab","major neurocognitive disorder","polypharmacy","health outcomes","pharmacists","home care","family medicine groups","deprescribing",{"date":593,"type":50},{"date":624,"type":50},"2021-09-27",{"date":238,"type":21},{"name":56,"class":57},2,{"id":629,"slug":630,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":11,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":636,"targetDuration":4,"studyType":22,"phases":638,"briefSummary":639,"conditions":640,"keywords":642,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":92},"100505586","retinal-detachment-outcomes-study-100505586","NCT05863312","REtinal Detachment Outcomes Study","Rhegmatogenous rEtinal Detachment With or withOut Scleral Buckle (REDOS) Trial: a Factorial, Randomized Controlled Trial","REDOS","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of rhegmatogenous retinal detachment\n\nExclusion Criteria, retinal detachment with:\n\n* Proliferative vitreoretinopathy (PVR) grade ≥C2\n* Chronic RRD with duration \\>3 months\n* Proliferative diabetic retinopathy with tractional retinal detachment (RD)\n* Macular holes\n* Epiretinal membrane grade 3 or 4\n* Traumatic RD\n* Giant retinal tears\n* Retinal dialysis\n* Foveoschisis\n* Wet age-related macular degeneration\n* Endophthalmitis\n* Acute retinal necrosis\n* Coats disease\n* Retinopathy of prematurity\n* Retinoschisis\n* Retinal colobomas\n* Prior glaucoma surgery or strabismus surgery (favoring PPV only)\n* Superior RD extent less than 3 clock hours (favoring PPV only)",{"count":637,"type":21},560,[24],"Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair. The purpose of this factorial, single-blind, randomized controlled trial is to analyze and compare the surgical outcomes, functional visual outcomes, complications, and quality of life associated with RRD repair using (A) pars plana vitrectomy only (PPV) or PPV with scleral buckle (PPV-SB) and (B) sulfur hexafluoride gas (SF6) or perfluoropropane gas (C3F8) tamponade.\n\nMethods: Eligible patients with moderately complex RRD will be randomized 1:1 to PPV or PPV-SB and 1:1 to SF6 or C3F8 gas tamponade. Approximately 560 patients will be recruited to be able to detect a difference of around 10% in SSAS rate between groups. Patients will be followed using multimodal imaging and quality of life questionnaires before and after the surgical repair until 1 year postoperative. The primary outcome will be single surgery anatomic success (SSAS), defined as absence of reoperation for recurrent RRD in the operating room. Secondary outcomes will be pinhole visual acuity (PHVA) at 8-10 weeks and 6 months, final best-corrected visual acuity (BCVA), final retina status (i.e., attached or detached), time to onset of RRD recurrence, severity and number of complications, and questionnaire results.\n\nDiscussion: This will be the first 2 × 2 factorial randomized controlled trial examining repair techniques in primary RRD. It will also be the first randomized controlled trial to compare gas tamponade between the two most common agents. Notably, it will be adequately powered to detect a clinically significant effect size. The use of multimodal imaging will also be a novel aspect of this study, allowing us to compare head-to-head the impact of adding an SB to the retina's recovery after RRD repair and of differing gas tamponades. Until now, the treatment of RRD has been largely guided by pragmatic retrospective cohort studies. There is a lack of strong evidence guiding therapeutic decisions and this trial will address (1) whether supplemental SB is justified and (2) whether longer duration gas tamponade with C3F8 is necessary.",[641],"Retinal Detachment",[643,644,645,646,647,648,649,650,651,652],"Pars plana vitrectomy","Scleral buckle","Rhegmatogenous retinal detachment","Proliferative vitreoretinopathy","Anatomic success","Visual acuity","Retinal displacement","Postoperative pain","Quality of life","Complications","2023-11-17",{"date":655,"type":50},"2023-11-18",{"date":657,"type":50},"2023-09-26",{"date":659,"type":21},"2028-07",{"name":56,"class":57},{"id":662,"slug":663,"hasResults":11,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":4,"eligibilityCriteria":667,"healthyVolunteers":345,"sex":153,"minAge":18,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":670,"conditions":671,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":92},"100266176","biobank-on-prematurity-preeclampsia-and-other-pregnancy-complications-100266176","NCT02744365","Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications","Biobank of Data and of Human Biological Samples on Prematurity, Preeclampsia and Other Pregnancy Complications","Inclusion Criteria:\n\n* (specific to each study)\n\nExclusion Criteria:\n\n* pregnant women \\\u003C18 years old at recruitment\n* negative fetal heart at recruitment\n* women not able to provide an informed consent to the study",{"count":669,"type":21},7845,"The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.",[672,673,674,675],"Preeclampsia","Preterm Birth","Pregnancy Complications","Fetal Anomalies","2022-03-14",{"date":678,"type":50},"2022-03-16",{"date":680,"type":50},"2015-04",{"date":682,"type":21},"2028-04",{"name":56,"class":57},""]